Journal of Cancer Prevention 2015; 20(4): 241-249
Published online December 30, 2015
© Korean Society of Cancer Prevention
Soojung Jin1,2, Hyun-Jin Park1, You Na Oh1, Hyun Ju Kwon1,2, Jeong-Hwan Kim1, Yung Hyun Choi1,3,4, and Byung Woo Kim1,2
1Blue-Bio Industry Regional Innovation Center, Dong-Eui University, Busan, Korea, 2Department of Life Science and Biotechnology, College of Natural Sciences and Human Ecology, Dong-Eui University, Busan, Korea, 3Department of Biochemistry, College of Korean Medicine, Dong-Eui University, Busan, Korea, 4Anti-Aging Research Center, Dong-Eui University, Busan, Korea
Correspondence to :
Byung Woo Kim, Blue-Bio Industry Regional Innovation Center, Dong-Eui University, 176 Eomgwang-ro, Busanjin-gu, Busan 47340, Korea, Tel: +82-51-890-2900, Fax: +82-505-182-6951, E-mail: email@example.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Inhibitory effect of EEOM on cell growth and proliferation was determined by WST assay in various cancer cells. To investigate the mechanisms of EEOM-mediated cytotoxicity, HepG2 cells were treated with various concentration of EEOM and analyzed the cell cycle arrest and apoptosis induction by flow cytometry, Western blot analysis, 4,6-diamidino-2-phenylindole (DAPI) staining and DNA fragmentation. EEOM showed the cytotoxic activities in a dose-dependent manner in various cancer cell lines but not in normal cells, and HepG2 cells were most susceptible to EEOM-induced cytotoxicity. EEOM induced G2/M arrest in HepG2 cells associated with decreased expression of cyclin-dependent kinase 1 (CDK1), cyclin A and cylcin B, and increased expression of phospho-checkpoint kinase 2, p53 and CDK inhibitor p21. Immunofluorescence staining showed that EEOM-treated HepG2 increased doublet nuclei and condensed actin, resulting in cell rounding. Furthermore, EEOM-mediated apoptosis was determined by Annexin V staining, chromatin condensation and DNA fragmentation. EEOM caused upregulation of FAS and Bax, activation of caspase-3, -8, -9, and fragmentation of poly ADP ribose polymerase. These results suggest that EEOM efficiently inhibits proliferation of HepG2 cells by inducing both G2/M arrest and apoptosis via intrinsic and extrinsic pathways, and EEOM may be used as a cancer chemopreventive agent in the food or nutraceutical industry.
Inhibitory effect of EEOM on cell growth and proliferation was determined by WST assay in various cancer cells. To investigate the mechanisms of EEOM-mediated cytotoxicity, HepG2 cells were treated with various concentration of EEOM and analyzed the cell cycle arrest and apoptosis induction by flow cytometry, Western blot analysis, 4,6-diamidino-2-phenylindole (DAPI) staining and DNA fragmentation.
EEOM showed the cytotoxic activities in a dose-dependent manner in various cancer cell lines but not in normal cells, and HepG2 cells were most susceptible to EEOM-induced cytotoxicity. EEOM induced G2/M arrest in HepG2 cells associated with decreased expression of cyclin-dependent kinase 1 (CDK1), cyclin A and cylcin B, and increased expression of phospho-checkpoint kinase 2, p53 and CDK inhibitor p21. Immunofluorescence staining showed that EEOM-treated HepG2 increased doublet nuclei and condensed actin, resulting in cell rounding. Furthermore, EEOM-mediated apoptosis was determined by Annexin V staining, chromatin condensation and DNA fragmentation. EEOM caused upregulation of FAS and Bax, activation of caspase-3, -8, -9, and fragmentation of poly ADP ribose polymerase.
These results suggest that EEOM efficiently inhibits proliferation of HepG2 cells by inducing both G2/M arrest and apoptosis via intrinsic and extrinsic pathways, and EEOM may be used as a cancer chemopreventive agent in the food or nutraceutical industry.
Keywords: Anticancer effect, Apoptosis, Cell cycle arrest, Hep G2 cells,
Hepatic cancer, a cancer that originates in the liver, is the sixth most common cancer and the second leading cause of cancer death in the world.1,2 In 2012, it occurred in 782,000 cases and resulted in 746,000 deaths, which was 9.1% of total cancer death.2 Due to the limitation of hepatic cancer treatment, such as surgery and transplantation, chemopreventive and chemotherapeutic approaches of naturally occurring compounds and extracts have received increasing attention in recent years.3–6
Cancer is characterized with an unregulated cell growth to invade or spread out to other organs of the body.7 For their abnormal cell growth, cancer cells can undergo limitless replication by deregulation of cell cycle and evade apoptosis. Therefore, inducing the cell cycle arrest and apoptosis of cancer cells is being an outstanding strategy for cancer chemoprevention and chemotherapeutics.8 It has been reported that many natural compounds and extracts are modulating cell cycle regulation and apoptosis.9–11 Cell cycle progression is controlled by cyclin-dependent kinase (CDK)/cyclin complexes, and CDK1/cyclin A and CDK1/cyclin B complexes are the key molecules of G2/M checkpoint.12 The activation of CDK/cyclin complex promotes cell cycle progression, while most of damage signals of cells induce cell cycle arrest by activating p53 via CHK2 to repair damaged DNA.13 Activated p53 induces the transcription of p21, a CDK inhibitor, which can suppress G2/M transition by the inactivation of CDK/cyclin complex.14
Apoptosis, programmed cell death, occurs in multicellular organisms and plays an important role in the regulation and maintenance of physiological conditions. It leads to various biochemical events including cell shrinkage, blebbing, nuclear fragmentation, and chromatin condensation.15 The mechanisms of apoptosis are divided into two pathways. One is the extrinsic pathway via death receptor and the other is the mitochondrial intrinsic pathway.16 The ligation of death receptors and their ligands induces the formation of a death-inducing signaling complex, followed by the caspase-8 activation. Activated caspase-8 can transmit the apoptotic signals both in directly via caspase-3 activation and in indirectly via activation of pro-apoptotic B-cell lymphoma 2 (Bcl-2) family proteins.17 Activation of pro-apoptotic Bcl-2 family proteins can induce the mitochondrial permeabilization, resulting in the release of cytochrome
The ethanol extract of
Human hepatocellular carcinoma HepG2, human colon adenocarcinoma HT29, human lung adenocarcinoma A549 and human fetal lung cells IMR90 cells were purchased from American Type Culture Collection (ATCC; Rockville, MD, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS, penicillin and streptomycin at 37°C and 5% CO2.
Measurement of cell viability was determined using the EZ-Cytox cell viability assay kit (Daeillab, Seoul, Korea). Cells were plated at a density of 2 to 5 × 104 cells/well in 24-well plates and treated with media containing DMSO as control or various concentrations of EEOM for 48 hours. EZ-Cytox assay reagent (10 μL) was added to each cell culture well, and the mixture was incubated for 30 minutes at 37°C. The absorbance was measured at 450 nm using a plate reader (Beckman Coulter, Fullerton, CA, USA). For morphological study, HepG2 cells were treated with EEOM for 48 hours and directly photographed with an inverted microscope using Axio Vision program.
The effects of EEOM on the cell cycle in HepG2 cells were examined using the MuseTM Cell Cycle kit (Merck Millipore, Darmstadt, Germany) according to the manufacturer’s instructions. Briefly, cells (1 × 105 cells/well) were plated in 6-well plate and treated with 0.1% DMSO as vehicle control or with various concentration of EEOM for 48 hours. The cells were then harvested, washed once with PBS, and fixed in cold 70% ethanol for 3 hours at −20°C. Fixed cells were centrifuged at 300 ×
EEOM-treated cells were treated with lysis buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM ethylenediaminete-traacetic acid [EDTA], 1 mM ethylene glycol tetraacetic acid, 1% Triton X-100, 1 μg/mL leupeptin, 1 mM phenylmethylsulfonyl fluoride) for 15 minutes on ice, disrupted by sonication and centrifuged for 30 minutes at 13,000 rpm. For preparation of cytosolic proteins, the sonication process of the above procedure was omitted.20 The proteins in the supernatant were collected and the concentration of protein was determined by Bradford method. For Western blot analysis, 30 to 50 μg/mL of proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted onto nitrocellulose membranes. Blots were incubated at 4°C overnight with specific primary antibodies followed by horseradish peroxidase-conjugated secondary antibodies and visualized by an enhanced chemiluminescence detection system (FluoChem® FC2; AlphaInnotech, San Leandro, CA, USA) using Western blotting luminol reagent (Santa Cruz Biotechnology, Dallas, TX, USA). CDK1, Cyclin A, Cyclin B, p53, Fas, Bax, caspase-3, caspase-8, caspase-9, PARP, actin primary antibodies and peroxidase-conjugated secondary antibodies were from Santa Cruz Biotechnology. Primary antibodies against CHK2, p-CHK2 (Thr68), p-p53 (Ser20), p21, and Bcl-2 were purchased from Cell Signaling Technology (Beverly, CA, USA).
The cells (2.5 × 104 cells/well) were plated in 8-chamber slides and treated with 0.1% DMSO as vehicle control or with various concentration of EEOM for 48 hours after serum starvation. The cells were fixed in 4% formaldehyde for 15 minutes at room temperature and rinsed three times in PBS. Non-specific interactions were blocked by normal donkey serum in 0.3% Triton X-100 for 1 hour, and then cells were incubated with primary antibody (goat anti-actin antibody; Santa Cruz Biotechnology) at 4°C overnight. After washing, cells were incubated with fluoresce in isothiocyanate (FITC)-labelled secondary antibody (donkey anti-goat immunoglobulin G-FITC; Santa Cruz Biotechnology) for 1 hour at room temperature. Cells were rinsed with PBS for three times and then stained with 4′,6-diamidino-2-phenylindole (DAPI; Sigma, St. Louis, MO, USA) for 10 minutes. After mounting, the stained cells were observed using fluorescence microscope (Carl Zeiss, Jena, Germany).
Apoptotic cells were measured using MuseTM Annexin V & Dead Cell Kit (Merck Millipore) according to the manufacturer’s instructions. In brief, HepG2 cells were treated with vehicle control or various concentrations of EEOM for 48 hours. Cells were harvested, washed and resuspended in 1% FBS/PBS. Cells were then mixed with an equal volume of MuseTM Annexin V & Dead Cell reagent and incubated for 20 minutes at room temperature in the dark. Without washing, cells were analyzed with the MuseTM Cell Analyzer and the Muse analysis software.
EEOM-treated cells were fixed with 4% formaldehyde for 20 minutes at room temperature. Fixed cells were permeabilized with 0.5% Triton X-100 in PBS for 10 minutes at room temperature. After washing with PBS, cells were incubated with 1 μg/mL of DAPI for 10 minutes and then washed three times in PBS. Apoptotic nuclei (condensed chromatin) were examined by fluorescence microscopy (Carl Zeiss).
After treatment of HepG2 cells with EEOM, harvested cells were lysed with a hypotonic lysis buffer (10 mM Tris-HCl [pH 7.4], 5 mM EDTA [pH 8.0], 0.2% Triton X-100) for 30 minutes on ice, followed by centrifugation at 12,000 ×
The data are presented as the mean ± SD from at least three independent experiments. Statistical comparisons between groups were performed by IBM SPSS program ver. 21 (IBM Co., Armonk, NY, USA) followed by Student
To investigate the anti-cancer activity of EEOM, we first examined the effect of EEOM on cancer cell growth using human hepatocellular carcinoma HepG2 cells, human colon adenocarcinoma HT29 cells and human lung adenocarcinoma A549 cells. As shown in Figure 1A, EEOM inhibited the growth of cancer cell lines in a dose-dependent manner and HepG2 cells were most susceptible to EEOM-induced cytotoxicity. Increasing concentrations of EEOM caused increasing floating cells and decreasing viable adherent HepG2 cells (Fig. 1B). However, EEOM did not show any significant inhibitory effect of proliferation in human normal fetal lung IMR90 cells. Therefore, we decided to examine the molecular mechanism of cytotoxic activity of EEOM in HepG2 cells.
To elucidate the cytotoxic effect of EEOM in HepG2 cells, cell cycle analysis was performed by flow cytometry. Cell population in G2/M phase was increased in a dose-dependent manner, accompanied by a decrease in the G0/G1 and S phases (Fig. 2A). As shown in Figure 2B, the percentage of cells in G2/M phase was increased from 27.9% to 52.8% by EEOM treatment (50 μg/mL). By the treatment with 100 μg/mL of EEOM, cells in G2/M phase were slightly decreased, whereas cells in SubG1 phase were increased compared to those of 50 μg/mL treatment (Fig. 2A). We next examined the expression of G2/M transition-related proteins by Western blot analysis to understand the molecular basis for the EEOM-induced G2/M arrest. As shown in Figure 2C, EEOM significantly decreased the protein levels of CDK1, cyclin A and cyclin B in a dose-dependent manner. Since it is well studied that CDK/cyclin complex can be negatively regulated by CHK2/p53 pathway,14 we determined the effect of EEOM on p53 pathway. Figure 2D showed that EEOM activated CHK2 via phosphorylation, and induced the expression and phosphorylation of p53 in a dose-dependent manner. The expression of CDK inhibitor p21, a downstream protein of p53, was increased by EEOM. However, the significant difference was not found in the expression of Cdc25C. These results indicate that EEOM brings about a remarkable G2/M arrest by p21 induction via CHK2/p53 pathway in HepG2 cells.
In order to further examine the morphological changes of EEOM-mediated G2/M arrest, we performed immunofluorescence staining with anti-actin antibody and DAPI. As shown in Figure 3, the shape of HepG2 cells was flattened and polygonal with well-organized actin fibers in the absence of EEOM treatment. On the contrary, EEOM-treated cells (Fig. 3 arrows) showed clustering of actin fibers and doublet nuclei mostly joined or bridged together. Moreover, some cells (Fig. 3 arrowheads) treated with 100 μg/mL of EEOM showed the condensation of nucleus and aggregation of actin, resulting in cell rounding.
Since HepG2 cells in SubG1 phase were increased by EEOM treatment (Fig. 2A), EEOM-mediated apoptosis was examined by flow cytometry analysis using Annexin V/7-Aminoactinomycin D (7-AAD) double staining. EEOM increased both early apoptotic (Annexin V+/7-AAD−) and late apoptotic cells (Annexin V+/7-AAD+) in a dose-dependent manner (Fig. 4A). According to Figure 4B, the percentage of apoptotic (Annexin V+) cells was increased from 4.03% to 35.56% by treatment with 100 μg/mL of EEOM. As nuclear condensation and DNA fragmentation are the remarkable characteristics of apoptosis,15 we next confirmed the EEOM-induced apoptosis by using DAPI staining and DNA fragmentation assay. As shown in Figure 4C, apoptotic bodies with chromatin condensation were observed in EEOM-treated HepG2 cells in a concentration-dependent manner. Clumpy chromatin condensation was easily detected in 100 μg/mL EEOM-treated HepG2 cells. Figure 4D showed that the chromosomal DNA of HepG2 cells was degraded by EEOM, resulting in the broad smearing and fragmented bands.
In order to investigate the effect of EEOM on the expression and activation of apoptosis-related molecules in the protein levels, we performed Western blot analysis. As shown in Figure 5A, we observed the upregulation of Fas, a death receptor, and Bax, a pro-apoptotic Bcl-2 family protein, in a dose-dependent manner. Activation of caspases, including caspase-3, -8 and -9, and the cleavage of PARP occurred by EEOM treatment in a dose-dependent manner (Fig. 5B).
In the present study, the anti-cancer activity of O.
Cell cycle dysregulation is a critical characteristic of tumor cells and regulation of proteins mediated cell cycle processes is an important strategy for the chemoprevention and chemotherapy of cancer.21,22 DNA damage or incomplete DNA replication brings about the inactivation of cell cycle checkpoint proteins, resulting in the inhibition of cell cycle progression to get the time required for DNA repair.23 Cell cycle progression is highly regulated by a series of cell cycle checkpoint proteins, the cyclins and CDKs.24,25 Among various cell cycle checkpoint proteins, a complex between CDK1 and cyclin A or CDK1 and cyclin B is involved in the process of G2/M transition.26,27 The activity of CDK/cyclin complex is negatively regulated to induce cell cycle arrest by p53-dependent or p53-independent pathway. In the case of p53-dependent pathway, a CDK inhibitor, p21, was induced by p53 increased in DNA damaged cells for cell cycle arrest and then non-repaired cells may be eliminated by apoptosis via inducing Bax and repressing Bcl-2 activity.28 On the other hand, in p53-independent pathway, damage signals of cells inactivate Cdc25C, an activator of CDK1/cyclin B complex.29,30
Our data revealed that 50 μg/mL and 100 μg/mL of EEOM induced HepG2 cell accumulation in G2/M phase and subG1 phase, respectively. These results suggest that EEOM-mediated cell cycle arrest is followed by apoptosis. Western blot analysis showed that EEOM increased the expression of p53 and p21, a CDK inhibitor, leading to G2/M arrest. The phosphorylation of CHK2 and p53 was also increased by EEOM, indicating that activated CHK2 triggers p53 phosphorylation to increase the stability of p53.31,32 However, EEOM did not show any big difference in the protein levels of Cdc25C. These results suggest that EEOM-mediated G2/M arrest occurs by inhibition of CDK/cyclin complex via p53-dependent p21 induction. In addition, immunofluorescence staining using antibody against actin and DAPI identified that EEOM-treated HepG2 cells have double nuclei and condensed actin, showing cell rounding. Based on the reports that the actin cytoskeleton of eukaryotic cells undergoes dynamic changes and remodeling during cell division cycle and apoptosis,33,34 our data suggest that EEOM may suppress the cytokinesis during the mitosis and cause the cytoskeletal changes to finally induce cell rounding, one of the characteristics of apoptosis.
Furthermore, EEOM-mediated apoptosis was also confirmed by Annexin V/7-AAD double staining, nuclear condensation and DNA fragmentation. Caspases, a family of cysteine proteases, are involved in apoptosis and activated by cleavage at a post-translational level.35 It has been well defined that apoptosis is induced by extrinsic and intrinsic pathways and increased Fas can activate caspase-8 and caspase-3 cascade via extrinsic pathway.36 By intrinsic pathway, released cytochrome c forms apoptosome with apoptotic protease activating factor-1, leading to cleavage of caspase-9 and activation of caspase-3.37 In this study, EEOM increased the expression of Fas and Bax, a pro-apoptotic member of Bcl-2 family. The caspase cascade, such as caspase-8, caspase-9, and caspase-3, was also activated by EEOM. These results strongly demonstrated that EEOM can induce apoptosis via both extrinsic and intrinsic pathways in HepG2 cells.
In conclusion, we found that EEOM efficiently induces cell cycle arrest at G2/M phase and apoptosis via both extrinsic and intrinsic pathways in HepG2 cells, followed by the suppression of cell proliferation. Our results show the anti-cancer activity of EEOM and its mode of action, which suggests that EEOM may be a possible nutraceutical candidate for chemoprevention and chemotherapy of cancer. Further studies will be required to identify the bioactive compound(s) of EEOM for its anti-cancer effect.
This work was supported by the Dong-Eui University Grant (2015AA102) and Blue-Bio Industry Regional Innovation Center (RIC08-06-07) at Dong-Eui University as a RIC program under Ministry of Trade, Industry and Energy (MOTIE) and Busan city.
No potential conflicts of interest were disclosed.
You Na Oh, Soojung Jin, Hyun-Jin Park, Hyun Ju Kwon, and Byung Woo KimJournal of Cancer Prevention 2016; 21(4): 249-256 https://doi.org/10.15430/JCP.2016.21.4.249
Ji-Young Hong, Hwa-Jin Chung, Song Yi Bae, Trinh Nam Trung, KiHwan Bae, and Sang Kook LeeJournal of Cancer Prevention 2014; 19(4): 273-278 https://doi.org/10.15430/JCP.2014.19.4.273
Hyun Il Jung, Byeng Wha Son and Gun-Do KimCancer prevention research 2012; 17(1): 45-55